State Street Corp Has $53.28 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

State Street Corp lessened its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.5% during the third quarter, HoldingsChannel reports. The firm owned 2,371,271 shares of the company’s stock after selling 337,262 shares during the quarter. State Street Corp’s holdings in Nurix Therapeutics were worth $53,282,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Amalgamated Bank boosted its stake in Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares in the last quarter. Quarry LP grew its holdings in shares of Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares during the last quarter. International Assets Investment Management LLC increased its position in Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after purchasing an additional 4,119 shares in the last quarter. Finally, Quest Partners LLC lifted its stake in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the last quarter.

Insider Activity

In other Nurix Therapeutics news, insider Christine Ring sold 3,290 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $25.00, for a total transaction of $82,250.00. Following the transaction, the insider now owns 24,592 shares in the company, valued at approximately $614,800. This represents a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares of the company’s stock, valued at $905,661. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,401 shares of company stock worth $437,453. Company insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NRIX. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $35.00 target price on the stock. Royal Bank of Canada lowered their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 14th. UBS Group started coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 price objective for the company. Finally, HC Wainwright boosted their target price on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.35.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $20.24 on Thursday. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.96 and a beta of 2.11. The stock’s 50-day moving average is $23.58 and its 200 day moving average is $22.28. Nurix Therapeutics, Inc. has a one year low of $7.65 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.